Arcutis: Reformulating dermatology

Backed by dermatology veterans, Arcutis is developing topical reformulations to increase the efficacy and safety of skin disease drugs

Arcutis Inc. is using its founders’ topical reformulation expertise to develop safer and less expensive therapeutics against known targets to treat dermatology patients who aren’t eligible for biologics.

Frazier Healthcare launched the company in 2016 to address the lack of new drugs in dermatology caused in part by large pharmas like Allergan plc and Valeant Pharmaceuticals International Inc. buying up small, innovative biotechs, Arcutis President and CEO Frank Watanabe told BioCentury.

“The pipeline for innovative dermatology drugs

Read the full 765 word article

User Sign In